Back to Journals » Vascular Health and Risk Management » Volume 8

The complex regulation of TGF-ß in cardiovascular disease

Authors Redondo S, Jorge Navarro-Dorado, Ramajo M, Medina U, Tejerina T

Received 14 July 2012

Accepted for publication 15 August 2012

Published 13 September 2012 Volume 2012:8 Pages 533—539


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Santiago Redondo, Jorge Navarro-Dorado, Marta Ramajo, Úrsula Medina, Teresa Tejerina

Department of Pharmacology, School of Medicine, Universidad Complutense, Madrid, Spain

Abstract: Transforming growth factor β (TGF-β1) is a pleiotropic cytokine with many and complex effects in cell and tissue physiology. This is made possible by a very complex and interwoven signaling system, whose regulation continues to be the focus of a growing line of research. This complex regulation translates to a key role in cardiovascular physiology, hemostasis, and the blood–vessel interface. In accordance with this, the TGF-β1 pathway appears to be deregulated in related disorders, such as atherosclerotic vascular disease and myeloproliferative syndromes. It is expected that the growing amount of experimental and clinical research will yield medical advances in the applications of knowledge of the TGF-β1 pathway to diagnosis and therapeutics.

Keywords: transforming growth factor beta, pathway, Smads, non-Smads, atherosclerosis, myeloproliferative syndromes

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other article by this author:

Emerging hematological targets and therapy for cardiovascular disease: From bench to bedside

Ana Villegas, Fernando A Gonzalez, Leopoldo Llorente, Santiago Redondo

Biologics: Targets and Therapy 2008, 2:397-407

Published Date: 12 September 2008

Readers of this article also read:

Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus

Beltrán LM, Rubio-Navarro A, Amaro-Villalobos JM, Egido J, García-Puig J, Moreno JA

Vascular Health and Risk Management 2015, 11:35-48

Published Date: 6 January 2015

Sex-specific relationships between adverse childhood experiences and chronic obstructive pulmonary disease in five states

Cunningham TJ, Ford ES, Croft JB, Merrick MT, Rolle IV, Giles WH

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1033-1043

Published Date: 26 September 2014

Lower extremity amputation in peripheral artery disease: improving patient outcomes

Swaminathan A, Vemulapalli S, Patel MR, Jones WS

Vascular Health and Risk Management 2014, 10:417-424

Published Date: 16 July 2014

Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients

Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Terleira-Fernández AI, Vargas-Castrillón E, Rocha E

Vascular Health and Risk Management 2013, 9:207-228

Published Date: 8 May 2013

The influence of perivascular adipose tissue on vascular homeostasis

Szasz T, Bomfim GF, Webb RC

Vascular Health and Risk Management 2013, 9:105-116

Published Date: 28 March 2013

The potential benefit of stem cell therapy after stroke: an update

Banerjee S, Williamson DA, Habib N, Chataway J

Vascular Health and Risk Management 2012, 8:569-580

Published Date: 10 October 2012

Rivaroxaban in atrial fibrillation

Giorgi MA, Miguel LS

Vascular Health and Risk Management 2012, 8:525-531

Published Date: 30 August 2012